Goodly Technologies GmbH is the successor company to Goodly Innovations, which was acquired by BioNTech SE in 2023. Goodly develops software for regulated industries such as pharmaceuticals and medical technology. Our team has a long standing of practical experience in developing validated, auditable solutions and works in accordance with GxP, CE/MD and comparable standards. We transform complex regulations into agile products.
Among other things, we develop XR solutions for ophthalmology to simplify, democratize and modernize clinical tests, specifically for seniors and underdeveloped areas. For pharmaceutical production, our team has developed innovative, compliant software that optimizes digital workflows and documentation while supporting data integrity through its design. Complementing these products, our AI system governance and training platform helps companies use AI responsibly and comply with the EU AI Act Regulation in a clear and transparent manner: interactive assessments, role-based training, policy templates and evidence collection.
Compliance is not an afterthought – it is part of our philosophy. We place a fundamental emphasis on validation, traceability and user-friendliness so that teams can act faster without compromising on quality or safety. Thanks to our cross-domain expertise (including XR, AI, clinical and manufacturing), we can apply best practices where they offer a real advantage. Our approach transforms regulatory obligations into intuitive, repeatable workflows, reducing risk, accelerating time to market and opening up new markets. With Goodly, regulated innovations become practical, scalable and audit-ready.